Ravata's technology delivers gene-editing agents like CRISPR into the embryos of mice. Unlike bulk-electroporators, the RIZE targets sub-portions of an embryo's membrane to maximize delivery efficiency and cell viability. At peak performance a 47% cost reduction and 50% reduction of animals used in mouse-model production has been demonstrated.
Ravata Individual Zygote Electroporator
Capture and Deliver Reagent to Many Zygotes in Parallel
Target Sub-Sections of the Membrane to Maximize Delivery
More than 80% CRISPR KO Efficiency and Viability
Fully Automated Processes with GUI Control
Arshia Firouzi (CoFounder, CEO)
Arshia is the co-founder and CEO of Ravata Solutions. A UC Davis Electrical Engineering alumnus, he has a diverse range of experiences having developed software and hardware for HVAC sensor systems, assisted in deep-space gravitational lensing research, and analyzing bio-membrane acid filtration. When Arshia finds free time he enjoys playing golf, tinkering with IoT devices, and backpacking.
Gurkern Sufi (CoFounder, COO)
Gurkern Sufi is the co-founder and COO at Ravata Solutions. He is a graduate of UC Davis’ Biotechnology program and has previously worked on projects ranging from evaluating therapeutic effectiveness for infantile necrotizing enterocolitis treatments in non-human primate models and performing clinical analysis on the effects of cardiac ablation as a treatment for atrial fibrillation to quantifying seasonal effects on biosynthesis of metabolites in Walnuts. Recreationally Gurkern enjoys participating in his adult soccer league, cycling, and experimenting with creative culinary creations.